Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR ® artificial intelligence (AI) platform to accelerate drug discovery, today announced that the ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

Evidence-based recommendations on zanubrutinib for treating relapsed or refractory mantle cell lymphoma in adults who have had 1 line of treatment only ...

A large-scale national study of primary central nervous system lymphoma (PCNSL) in England has revealed stark differences in ...

Data from population-based studies have shown an increased incidence of certain types of neoplasms in patients younger than 50 years (early-onset cancer [EOC]); however, little information is derived ...

This trial compared ofatumumab with rituximab for people with diffuse large B cell or follicular lymphoma.

But a population-based study consisting of 11,905 participants from Swedish National cancer registry published in 2024 found an increase in the incidence of Lymphoma by 21% among those with tattoos.